![]()
|
|
||||||||
J Biol Chem, Vol. 274, Issue 34, 23695-23698, August 20, 1999
From the Cornell University, Division of Nutritional Sciences, Savage Hall, Ithaca, New York 14853
| |
ABSTRACT |
|---|
|
|
|---|
The pleiotropic effects of retinoic acid (RA) in
mammalian cells are mediated by two classes of proteins: the retinoic
acid receptors (RAR) and cellular retinoic acid-binding proteins
(CRABP-I and CRABP-II). Here we show that expression of CRABP-II, but
not CRABP-I, markedly enhanced RAR-mediated transcriptional activation of a reporter gene in COS-7 cells. The equilibrium dissociation constants of complexes of CRABP-I or CRABP-II with RA were found to
differ by 2-fold. It is thus unlikely that the distinct effects of the
two proteins on transactivation stem from differential ligand-binding
affinities. The mechanisms by which RA transfers from the CRABPs to RAR
were thus investigated directly. The rate constant for movement of RA
from CRABP-II, but not from CRABP-I, to RAR strongly depended on the
concentration of the acceptor. The data suggest that transfer of RA
from CRABP-I to RAR involves dissociation of the ligand from the
binding protein, followed by association with the receptor. In
contrast, movement of RA from CRABP-II to the receptor is facilitated
by a mechanism that involves direct interactions between CRABP-II and
RAR. These findings reveal a striking functional difference between
CRABP-I and CRABP-II, and point at a novel mechanism by which the
transcriptional activity of RA can be regulated by CRABP-II.
Retinoic acid (RA)1 is
an important regulator of cell growth and differentiation both in fetal
and in adult tissues. Two classes of proteins are involved in mediating
the multiple biological activities of RA. One of these, the retinoic
acid receptors (RARs), encompasses ligand-inducible transcription
factors that belong to the superfamily of nuclear hormone receptors and
that are specifically activated by RA. RARs associate with the retinoid
X receptor (RXR) to form RAR-RXR heterodimers, which regulate
transcription following binding at the promoter regions of various
target genes and activation by their cognate ligands (1). Another class
of intra-cellular proteins that bind RA with a high affinity comprises
two homologous proteins, cellular RA-binding proteins I and II (CRABP-I
and CRABP-II). CRABPs are found in all vertebrates and are highly
conserved across species (2). The two CRABP isoforms display different
patterns of expression across cells and developmental stages. In the
adult, CRABP-I is expressed almost ubiquitously, whereas CRABP-II is only expressed in skin (2), uterus, ovary (3, 4), and in the choroid
plexus (5). Both CRABPs are widely expressed in the embryo, although
they do not usually co-exist in the same cells (6). The distinct
patterns of expression of CRABP-I and II suggest that they serve
different functions in the biology of RA, or, perhaps, that they
allow for accommodating different requirements for RA in
different tissues.
Although the genes for both CRABP isoforms from various species have
been cloned and characterized, neither the exact functions of these
proteins nor the distinct roles of the two isoforms are completely
understood at present. Interestingly, despite the high conservation of
CRABPs, mice in which these genes have been disrupted appear
essentially normal (7). It is usually proposed that CRABPs serve to
solubilize and protect their ligand in cytosol and that they transport
RA between different cellular compartments (2). It was suggested, for
example, that CRABPs act to deliver their ligand to the nucleus (8).
Indeed, it was recently demonstrated that both CRABP isoforms are
present not only in cytosol but also in the nuclei of cells (9).
It was also suggested that CRABP-I regulates the metabolic fate of its
ligand by directly affecting the activities of RA-metabolizing enzymes.
It was reported that the rate of degradation of RA in F9
teratocarcinoma cells increases upon elevation of the expression level
of CRABP-I (10). It was shown further that the sensitivity of F9 cells
to RA-induced differentiation is inversely correlated to the cellular
level of CRABP-I (11). Hence, it is currently believed that CRABP-I
moderates cellular response to RA by facilitating catabolism and/or by
sequestering RA, rendering it unavailable to nuclear receptors.
Little information is available regarding the specific biological role
of CRABP-II. Here, the kinetic patterns that govern the process by
which CRABPs deliver their ligand to RAR were examined and correlated
with their effects on RAR-mediated transcriptional activation. The
observations indicate that CRABP-II, but not CRABP-I, directly
interacts with RAR and that these protein-protein interactions markedly
facilitate the formation of the RAR·RA complex.
Proteins--
hRAR Transactivation Assays--
COS-7 cells were transfected with
pSG5 vector containing either CRABP-I or CRABP-II (2 µg), together
with DR-5-tk-CAT reporter plasmid (1 µg, see Ref. 23 for details) and
pCH110 (0.5 µg). Assays were carried out as described previously
(14).
Fluorescence Titrations--
were carried out as described
previously (16) and followed either by monitoring the ligand-induced
decrease of the fluorescence of the protein
( Transfer of RA from CRABP to Unilamellar
Vesicles--
Unilamellar vesicles of DOPC (Avanti Polar Lipids) were
prepared as described previously (20). Holo-CRABP-I or -II was mixed with vesicles, and RA transfer was monitored by following either the
fluorescence of the protein or the fluorescence of RA. Data were fitted
to a first order reaction.
Kinetics of Association of RA with CRABP--
Equimolar
solutions of CRABP and RA were mixed using a stopped-flow apparatus
(HiTech, Salisbury, UK), and complex formation was monitored by
following the time-dependent increase in RA fluorescence. Data were fitted to a second order equation.
Transfer of RA from CRABP to RAR--
holo-CRABP was mixed with
RAR at varying RAR/CRABP molar ratios in the range of 5-25. Transfer
was monitored by the time-dependent decrease in the
fluorescence of RA. Data were fitted to a first order equation.
CRABP-II, but Not CRABP-I, Enhances Transcriptional Activation by
RA--
To investigate whether either CRABP-I or CRABP-II affects the
transcriptional activity of RA, transactivation assays were carried
out. A CAT reporter construct containing the response element DR-5,
which specifically binds RAR-RXR heterodimers (21), was co-transfected
into COS-7 cells together with expression vectors for either CRABP-I or
CRABP-II, and the ability of RA to activate transcription of the
reporter gene was studied (Fig. 1).
Addition of RA induced expression of the reporter in a
dose-dependent fashion (Fig. 1, open bars).
Overexpression of CRABP-I had little effect on the RA-induced
activation (Fig. 1, gray bars). In contrast, expression of
CRABP-II markedly stimulated transactivation by RA (Fig. 1,
hatched bars) in this system.
The Equilibrium Dissociation Constants of Complexes of CRABP-I and
CRABP-II with RA Are Similar--
To examine whether functional
differences between CRABP-I and CRABP-II may stem from differences in
their RA binding affinity (19), Kd values
characterizing the association of RA with CRABP-I and CRABP-II were
measured. To this end, the kinetic parameters of the dissociation and
the association of complexes of RA with the binding proteins
(koff and kon,
respectively) were measured. The respective Kd
values were obtained by using the relationship Kd = koff/kon.
To withdraw RA from CRABP, unilamellar vesicles of DOPC, serving as a
"hydrophobic sink," were used (22). CRABP was pre-complexed with
RA, mixed with the vesicles, and movement of the ligand from the
protein to the vesicles was followed. RA fluoresces when bound to
CRABP-I or II, although it is not fluorescent when associated with
lipid vesicles (18). RA transfer from CRABP to vesicles could thus be
followed by monitoring the time-dependent decrease in the
fluorescent of the ligand. In this assay, because the amount of
vesicles used was sufficient to draw >95% of the ligand from the
protein, the rate constant of the observed reaction directly reflects
the rate constant for dissociation of RA from the protein (koff) (16, 20). Representative traces showing
transfer of RA from CRABP-I or CRABP-II to vesicles are shown in Fig.
2, a and b,
respectively, and the derived rate constants are listed in Table
I. The rate of association of the
CRABP·RA complexes was examined by mixing equimolar concentrations of
RA and protein and following the time-dependent enhancement
of the fluorescence of the ligand upon binding (Fig. 2, c
and d). These data were analyzed as described previously
(20) to yield kon (Table I). The data indicated
that kon for the two proteins are similar and close to the diffusion limit and that koff is
2-fold lower for CRABP-I versus CRABP-II, leading to a
2-fold higher ligand-binding affinity of the former.
CRABP-I and CRABP-II Deliver RA to RAR by Different
Mechanisms--
It is difficult to see how a 2-fold difference in the
Kd of CRABP-I and II may account for their distinct
effects on the transcriptional activity of RAR. We thus wondered
whether the functional differences between the two proteins may stem
from differences in the mechanisms by which they deliver their ligand to RAR. Theoretically, transfer of a ligand from a donor to an acceptor
protein may occur by one of two possible mechanisms. One pathway
involves initial dissociation of the ligand from the donor into the
aqueous phase, followed by association with the acceptor. In this case,
the rate-limiting step for the transfer reaction will be the
dissociation of the donor-ligand complex, and the rate constant of the
reaction will be independent of the nature or the concentration of the
acceptor (23). In a second scenario, the ligand will move from the
donor to the acceptor by "channeling," i.e. by a process
that involves direct protein-protein interactions and that bypasses the
aqueous phase. In this case, the rate of the reaction will be limited
by the frequency of productive collisions between the donor and the
acceptor and will become faster as the acceptor/donor ratio is increased.
Hence, the mechanism by which CRABP "delivers" RA to RAR can be
delineated by examining the dependence of the rate constants of ligand
transfer between the two proteins on the concentration of the acceptor
(RAR). As RA is an efficient fluorophore when bound to either CRABP but
not when associated with RAR, transfer could be followed by the
time-dependent decrease in RA fluorescence upon mixing of
holo-CRABP with apo-RAR. The rate constant for movement of the RA from
CRABP-I to RAR was independent of the concentration of the acceptor
(Fig. 3a), indicating that
movement of RA from CRABP-I to RAR requires prior dissociation of the
ligand from CRABP-I. To verify the accuracy of the fluorescence
measurements, the rate of transfer was also measured by monitoring
movement of 3H-RA from CRABP-I to RAR. Following mixing,
separation of the two proteins at different time points was affected by
addition of Ni2+ chelating beads which bind the his-tagged
RAR but not CRABP. Mixtures were centrifuged, and the remaining
CRABP-bound RA was measured by counting. The rate constant thus
obtained was essentially identical to that extracted from the
fluorescence assays (data not shown).
In contrast with CRABP-I, the pseudo first order rate constant for
movement of RA from CRABP-II to RAR (Fig. 3b) strongly depended on the concentration of the acceptor; a 5-fold increase in the
concentration of RAR facilitated that rate of transfer of RA from
CRABP-II to RAR by 5-fold. This behavior strongly indicates that
movement of RA from CRABP-II to RAR is mediated by direct protein-protein interactions between the two proteins.
Overall, the data reveal that while CRABP-I acts as a passive vehicle
for RA which binds and releases its ligand in response to shifts in
equilibrium conditions, CRABP-II delivers RA to RAR by "channeling"
between the two proteins. These observations show further that the
interactions between CRABP-II and RAR result in significant
facilitation of the formation of the RAR-RA complex and may be the
basis for the enhancing effect of CRABP-II on the RAR-mediated transactivation.
The Interactions between CRABP-II and RAR Are Transient--
To
further characterize the interactions that mediate transfer of RA
between CRABP-II and RAR, we attempted to demonstrate formation of a
stable complex between the two proteins. The following methods were
used: 1) chemical cross-linking (13), 2) electrophoresis under
nondenaturing conditions, 3) fluorescence anisotropy titrations (24,
25), 4) electrophoretic mobility-shift assays, intended to examine
whether cognate DNA may stabilize the complex (25). We could not detect
complex formation using any of these methods. It thus seems that the
interactions of CRABP-II·RAR complex is an unstable intermediate with
a short half-life.
Two classes of proteins are believed to be involved in regulating
the transcriptional activities of RA: the retinoid nuclear receptors
RAR and RXR, and the cellular RA-binding proteins CRABP-I and CRABP-II.
The mechanisms of action of retinoid receptors have become increasingly
understood in recent years. However, despite the striking level of
conservation of CRABP across species, which suggest that they play
critical roles in RA action, and although the remarkably different
expression profiles of the two CRABP isoforms suggest that they play
different roles in RA biology, neither the exact functions of these
proteins nor the nature of their distinct roles are clear at present.
The current study was thus undertaken to investigate possible
functional differences between CRABP-I and CRABP-II.
The data presented in Fig. 1 demonstrate that expression of CRABP-II
markedly stimulates the RA-induced transcriptional activity of RAR and
that, in contrast, CRABP-I has no effect on this activity. Hence, the
two proteins display remarkable functional differences.
It was previously shown that elevated expression of CRABP-I in F9
teratocarcinoma cells inhibits the transcriptional activity of RAR, and
it was suggested that CRABP-I directs RA to enzymes that catalyze its
degradation (10, 11). In contrast, the data in Fig. 1, in agreement
with previous studies carried out using CV-1 cells (26), show that
expression of CRABP-I had little effect on RA-induced transactivation
in COS-7 cells. It thus seems that the effect of CRABP-I on the
transcriptional activity of RAR depends on the particular cell type. It
is reasonable to suggest, for example, that CRABP-I inhibits the
transcriptional activity of RA only in cells that express
RA-metabolizing enzymes that are under its direct regulation. Such
enzymes were demonstrated to exist in F9 cells (11). To our knowledge,
metabolism of RA in either COS-7 or CV-1 has not been studied in depth.
The Kd values of complexes of RA with CRABP-I
and -II were found to differ by only 2-fold (Table I), suggesting that
it is unlikely that the functional differences between the two proteins stem from differential ligand-binding affinities. We thus set out to
examine whether CRABP-I and -II might deliver their ligand to RAR by
different mechanisms. Theoretically, there are two possible pathways by
which a ligand can move from a donor to an acceptor protein. Transfer
may proceed by dissociation of the ligand from the donor to the aqueous
phase, followed by association with the acceptor. In this scheme, the
rate of transfer will be limited by the rate of dissociation of the
donor-ligand complex. Alternatively, the ligand may transfer from the
donor to the acceptor by a process that is mediated by direct
protein-protein interactions. In this case, the rate of transfer will
depend on the probability of productive collisions between the two
proteins and will be faster as the acceptor/donor ratio is increased.
Studies of the kinetic patterns of the movement of RA between the
binding proteins and RAR (Fig. 3) demonstrated that transfer of RA from
CRABP-I to RAR is indicative of a process that requires prior
dissociation of the RA·CRABP-I complex (see Fig.
4a). This conclusion is also
supported by the observations that the rate constant for dissociation
of RA from CRABP-I was similar regardless of whether the acceptor was
RAR or lipid vesicles (Table I).
![]()
INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
![]()
EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
Lacking the terminal A/B domain
(RAR
AB) was obtained by overexpression in Escherichia
coli and purified as described previously (13). This protein
displays ligand-binding, DNA-binding, and dimerization properties that
are identical to those of the full-length protein (14). Bacterial
expression vectors for bCRABP-I and bCRABP-II (in pT7 vector) were
provided by David Ong (Vanderbilt University). These proteins were
expressed and purified as described (15).
ex = 280 nm,
em = 340 nm) (17) or the increase in fluorescence of RA upon binding to
CRABP (
ex = 360 nm,
em = 470 nm) (18). Titration curves were
corrected (24) and data fitted to a binding equation (19).
![]()
RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (39K):
[in a new window]
Fig. 1.
Effect of co-expression of CRABP-I and -II on
RA-induced transactivation. COS-7 cells were transiently
transfected with 2 µg of pSG5 (control), or hCRABP-I or
hCRABP-II expression vector, together with 1 µg of DR-5-tk-CAT
reporter plasmid. 0.5 µg of the
-galactosidase expression vector
CH110 was used as internal standard. Cells were treated with either
Me2SO or the denoted concentrations of RA for a period of
18 h. CAT activity, normalized for
-galactosidase activity, is
presented as -fold induction relative to control cells. Each
bar represents the mean ± S.E. from a representative
experiment (carried out in triplicate).

View larger version (42K):
[in a new window]
Fig. 2.
Rates of dissociation and association of
complexes of RA with CRABP-I or CRABP-II. Rates of dissociation of
RA from CRABP-I (a) or CRABP-II (b) were measured
as described under "Experimental Procedures." Holo-proteins were
mixed with vesicles of DOPC at a molar ratio of 20,000. Transfer was
followed by monitoring the time-dependent decrease in the
fluorescence of RA. Data were fitted to a first order reaction equation
to yield koff. Rates of association of RA with
CRABP-I (c) or CRABP-II (d) were monitored
following mixing solutions containing equimolar concentrations of the
binding protein and RA (final concentration 0.5 µM each).
Mixing was carried out using a stopped-flow apparatus in conjunction
with the fluorometer. The fluorescence of RA was monitored, and the
rate constant for association (kon) was obtained
by fitting the data to a second order reaction equation.
Parameters characterizing the interactions of RA with CRABPsa

View larger version (18K):
[in a new window]
Fig. 3.
Dependence of the rate of transfer of RA from
CRABP to RAR on the concentration of the acceptor. Holo-CRABP-I
(a) or holo-CRABP-II (b) (1 µM) was
mixed with RAR at concentrations of 5, 10, 21, or 25 µM.
Transfer of RA from the binding protein to the receptor was monitored
by measuring the time-dependent decrease in RA fluorescence
(
ex = 360 nm,
em = 470 nm) following mixing of holo-CRABP with RAR. Data were fitted to a
first order reaction equation to obtain the reaction rate
constants. The apparent half-life (t1/2) of the
transfer reactions are shown as a function of the concentration of RAR.
Data are presented as mean ± S.E. (n = 3-6),
except [RAR] = 21 µM where n = 2.
![]()
DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

View larger version (24K):
[in a new window]
Fig. 4.
Mechanisms of transfer of RA from CRABPs to
RAR. Schematic representations of the suggested pathways by which
CRABP-I (a) or CRABP-II (b) deliver RA to
RAR.
In contrast with CRABP-I, the pattern of movement of RA from CRABP-II to RAR was characteristic of a process that is mediated by direct interactions between the two proteins (see Fig. 4b). Further, the data showed that these interactions result in a significant facilitation of the delivery of RA to the receptor. Hence, CRABP-II enhances the transcriptional activity of RAR by directly interacting with the receptor, thereby facilitating the formation of the active RAR·RA complex. Interestingly, it was recently reported that ectopic expression of CRABP-II enhances transcriptional activation by RA in mammary carcinoma cell lines (27) and that expression of a CRABP-II antisense construct in SCC25 cells renders these cells less sensitive to RA-mediated inhibition of proliferation (12). No suggestions for the mechanism that may underlie these observations were put forward in these reports, but the results of the present work suggest that these effects were mediated by the CRABPII-dependent facilitation of the formation of holo-RAR. It is also worth noting that it has been reported that the expression of CRABP-II is elevated in cells that synthesize relatively large amounts of RA (5, 28, 29). These observations can be understood, in view of the present findings, to imply that increased physiological needs for RA require both an increase in RA synthesis and an up-regulation of CRABP-II, allowing for rapid delivery of newly synthesized RA to RAR.
Our efforts to demonstrate a stable complex between CRABP-II and RAR
failed despite utilization of multiple experimental approaches. It thus
seems that the interactions between the two proteins are transient in
nature and that the CRABP-II·RAR complex is a short-lived intermediate. Transient interactions that serve to channel ligands between proteins have been previously documented for several enzymes, for example within the purine biosynthetic pathway (30). In these
cases, similar to the present study, it was not possible to isolate a
stable complex between the proteins involved although it has been
established that direct protein-protein interactions indeed occur and
play an important role in this particular metabolic pathway. To the
best of our knowledge, the present work constitutes the first example
for channeling of a small ligand between two proteins for purposes
other than movement of a substrate down a metabolic pathway.
| |
ACKNOWLEDGEMENTS |
|---|
We thank Anuradha Budhu for measurements of rates of transfer of 3H-RA between CRABP-I and RAR. We are grateful to David Ong, for providing bacterial expression vectors for CRABP-I and CRABP-II, and to Hinrich Gronemeyer and Pierre Chambon, for cDNA for CRABP-I, CRABP-II, and RAR and for the DR5-tk-CAT reporter construct.
| |
FOOTNOTES |
|---|
* This work was supported by National Institutes of Health Grant CA68150 and Grant 5-T32-DK07158 (to D. D.) and by United States Department of Agriculture Grant 89-34115-4498.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
To whom correspondence should be addressed: Savage Hall, Cornell
University, Ithaca, NY 14853. Tel.: 607-255-2490; Fax: 607-255-1033; E-mail: nn14@cornell.edu.
| |
ABBREVIATIONS |
|---|
The abbreviations used are: RA, retinoic acid; RAR, retinoic acid receptor; CRABP, cellular retinoic acid-binding protein; RXR, retinoid X receptor; DOPC, dioleylphosphatidychloline.
| |
REFERENCES |
|---|
|
|
|---|
| 1. | Chambon, P. (1996) FASEB J. 10, 940-954[Abstract] |
| 2. | Ong, D. E., Newcomer, M. E., and Chytil, F. (1994) in The Retinoids: Biology, Chemistry and Medicine (Sporn, M. B. , Roberts, A. B. , and Goodman, D. S., eds), 2nd Ed. , pp. 288-317, Raven Press, NY |
| 3. |
Zheng, W. L.,
and Ong, D. E.
(1998)
Biol. Reprod.
58,
963-970 |
| 4. | Wardlaw, S., Bucco, R. A., Zheng, W. L., and Ong, D. E. (1997) Biol. Reprod. 56, 125-132[Abstract] |
| 5. | Yamamoto, M., Drager, U. C., Ong, D. E., and McCaffery, P. (1998) Eur. J. Biochem. 257, 344-350[Medline] [Order article via Infotrieve] |
| 6. | Maden, M. (1994) in Vitamin A in Health and Disease (Blomhoff, R., ed) , pp. 289-322, Marcel Dekker, NY |
| 7. |
Gorry, P.,
Lufkin, T.,
Dierich, A.,
Rochtte-Egly, C.,
Decimo, D.,
Dolle, P.,
Mark, M.,
Durand, B.,
and Chambon, P.
(1994)
Proc. Natl. Acad. Sci. U. S. A.
91,
9032-9036 |
| 8. | Takase, S., Ong, D. E., and Chytil, F. (1986) Arch. Biochem. Biophys. 247, 328-334[CrossRef][Medline] [Order article via Infotrieve] |
| 9. |
Gaub, M-P.,
Lutz, Y.,
Ghyselinck, N. B.,
Scheuer, I.,
Pfister, V.,
Chambon, P.,
and Rochette-Egly, C.
(1998)
J. Histochem. Cytochem.
46,
1103-1111 |
| 10. |
Boylan, J. F.,
and Gudas, L. J.
(1992)
J. Biol. Chem.
267,
21486-21491 |
| 11. | Boylan, J. F., and Gudas, L. J. (1991) J. Cell Biol. 12, 965-979 |
| 12. | Vo, H. P., and Crowe, D. L. (1998) Anticancer Res. 18, 217-224[Medline] [Order article via Infotrieve] |
| 13. | Kersten, S., Kelleher, D., Chambon, P., Gronemeyer, H., and Noy, N. (1995) Proc. Natl. Acad. Sci. U. S. A. 96, 10014-10017 |
| 14. | Chen, Z.-P., Iyer, J., Bourguet, W., Held, P., Mioskowski, C., Lebeau, L., Noy, N., Chambon, P., and Gronemeyer, H. (1998) J. Mol. Biol. 275, 55-65[CrossRef][Medline] [Order article via Infotrieve] |
| 15. | Jamison, R. S., Newcomer, M. E., and Ong, D. E. (1994) Biochemistry 33, 2873-2879[CrossRef][Medline] [Order article via Infotrieve] |
| 16. | Kersten, S., Dawson, M. I., Lewis, B. A., and Noy, N. (1996) Biochemistry 34, 3816-3824 |
| 17. | Cogan, U., Kopelman, M., Mokady, S., and Shinitzky, M. (1976) Eur. J. Biochem. 65, 71-78[Medline] [Order article via Infotrieve] |
| 18. |
Fiorella, P. D.,
Giguere, V.,
and Napoli, J. L.
(1993)
J. Biol. Chem.
268,
21545-21552 |
| 19. | Norris, A. W., Cheng, L., Giguere, V., Rosenberger, M., and Li, E. (1994) Biochim. Biophys. Acta 1209, 10-18[CrossRef][Medline] [Order article via Infotrieve] |
| 20. | Noy, N., and Xu, Z.-J. (1990) Biochemistry 29, 3878-3883[CrossRef][Medline] [Order article via Infotrieve] |
| 21. | Mangelsdorf, D. J., Umesono, K., and Evans, M. R. (1994) in The Retinoids: Biology, Chemistry and Medicine (Sporn, M. B. , Roberts, A. B. , and Goodman, D. S., eds), 2nd Ed. , pp. 319-349, Raven Press, NY |
| 22. |
Chen, Y.,
Houghton, L. A.,
Brenna, J. T.,
and Noy, N.
(1996)
J. Biol. Chem.
271,
20507-20515 |
| 23. | Daniels, C., Noy, N., and Zakim, D. (1985) Biochemistry 24, 3286-3292[CrossRef][Medline] [Order article via Infotrieve] |
| 24. | Lakowicz, J. R. (1983) Principles of Fluorescence Spectroscopy , pp. 112-150, Plenum Press, New York |
| 25. | Dong, D., and Noy, N. (1998) Biochemistry 37, 10691-10700[CrossRef][Medline] [Order article via Infotrieve] |
| 26. | Venepally, P., Reddy, L. G., and Sani, B. P. (1996) Biochemistry 35, 9974-9982[CrossRef][Medline] [Order article via Infotrieve] |
| 27. |
Jing, Y.,
Waxman, S.,
and Mira-y-Lopez, R.
(1997)
Cancer Res.
57,
1668-1672 |
| 28. | Zheng, W. L., Bucco, R. A., Schmitt, M. C, Wardlaw, S. A., and Ong, D. E. (1996) Endocrinology 137, 5028-5035[Abstract] |
| 29. | Bucco, R. A., Zheng, W. L., Davis, J. T., Sierra-Rievra, E., Osteen, K. G., Chaudhary, A. K., and Ong, D. E. (1997) Biochemistry 36, 4009-4014[CrossRef][Medline] [Order article via Infotrieve] |
| 30. | Rudolph, J., and Stubbe, J. (1995) Biochemistry 34, 2241-2250[CrossRef][Medline] [Order article via Infotrieve] |
This article has been cited by other articles:
![]() |
M. Zaitseva, B. J. Vollenhoven, and P. A.W. Rogers Retinoic acid pathway genes show significantly altered expression in uterine fibroids when compared with normal myometrium Mol. Hum. Reprod., August 1, 2007; 13(8): 577 - 585. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. J. Donato, J. H. Suh, and N. Noy Suppression of Mammary Carcinoma Cell Growth by Retinoic Acid: the Cell Cycle Control Gene Btg2 Is a Direct Target for Retinoic Acid Receptor Signaling Cancer Res., January 15, 2007; 67(2): 609 - 615. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Tozaki-Saitoh, S. Koizumi, Y. Sato, M. Tsuda, T. Nagao, and K. Inoue Retinoic Acids Increase P2X2 Receptor Expression through the 5'-Flanking Region of P2rx2 Gene in Rat Phaeochromocytoma PC-12 Cells Mol. Pharmacol., July 1, 2006; 70(1): 319 - 328. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. J. Donato and N. Noy Suppression of Mammary Carcinoma Growth by Retinoic Acid: Proapoptotic Genes Are Targets for Retinoic Acid Receptor and Cellular Retinoic Acid-Binding Protein II Signaling Cancer Res., September 15, 2005; 65(18): 8193 - 8199. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Wang and C. Montell Rhodopsin Formation in Drosophila Is Dependent on the PINTA Retinoid-Binding Protein J. Neurosci., May 25, 2005; 25(21): 5187 - 5194. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Arslan, L. I. Gold, K. Mittal, T.-C. Suen, I. Belitskaya-Levy, M.-S. Tang, and P. Toniolo Gene expression studies provide clues to the pathogenesis of uterine leiomyoma: new evidence and a systematic review Hum. Reprod., April 1, 2005; 20(4): 852 - 863. [Abstract] [Full Text] [PDF] |
||||
![]() |
X.-H. Li, B. Kakkad, and D. E. Ong Estrogen Directly Induces Expression of Retinoic Acid Biosynthetic Enzymes, Compartmentalized between the Epithelium and Underlying Stromal Cells in Rat Uterus Endocrinology, October 1, 2004; 145(10): 4756 - 4762. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. M. Janes, T. A. Ofstad, D. H. Campbell, F. M. Watt, and D. M. Prowse Transient activation of FOXN1 in keratinocytes induces a transcriptional programme that promotes terminal differentiation: contrasting roles of FOXN1 and Akt J. Cell Sci., August 15, 2004; 117(18): 4157 - 4168. [Abstract] [Full Text] [PDF] |
||||
![]() |
S.-K. Kim, J.-I. Yoo, B.-K. Cho, S. J. Hong, Y.-K. Kim, J.-A. Moon, J. H. Kim, Y.-N. Chung, and K.-C. Wang Elevation of CRABP-I in the Cerebrospinal Fluid of Patients With Moyamoya Disease Stroke, December 1, 2003; 34(12): 2835 - 2841. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Shaw, M. Elholm, and N. Noy Retinoic Acid Is a High Affinity Selective Ligand for the Peroxisome Proliferator-activated Receptor {beta}/{delta} J. Biol. Chem., October 24, 2003; 278(43): 41589 - 41592. [Abstract] [Full Text] [PDF] |
||||
![]() |
X.-H. Li and D. E. Ong Cellular Retinoic Acid-binding Protein II Gene Expression Is Directly Induced by Estrogen, but Not Retinoic Acid, in Rat Uterus J. Biol. Chem., September 12, 2003; 278(37): 35819 - 35825. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Manor, E. N. Shmidt, A. Budhu, A. Flesken-Nikitin, M. Zgola, R. Page, A. Yu. Nikitin, and N. Noy Mammary Carcinoma Suppression by Cellular Retinoic Acid Binding Protein-II Cancer Res., August 1, 2003; 63(15): 4426 - 4433. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Golovleva, S. Bhattacharya, Z. Wu, N. Shaw, Y. Yang, K. Andrabi, K. A. West, M. S. I. Burstedt, K. Forsman, G. Holmgren, et al. Disease-causing Mutations in the Cellular Retinaldehyde Binding Protein Tighten and Abolish Ligand Interactions J. Biol. Chem., March 28, 2003; 278(14): 12397 - 12402. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Despouy, J.-N. Bastie, S. Deshaies, N. Balitrand, A. Mazharian, C. Rochette-Egly, C. Chomienne, and L. Delva Cyclin D3 Is a Cofactor of Retinoic Acid Receptors, Modulating Their Activity in the Presence of Cellular Retinoic Acid-binding Protein II J. Biol. Chem., February 14, 2003; 278(8): 6355 - 6362. [Abstract] [Full Text] [PDF] |
||||
![]() |
N.-S. Tan, N. S. Shaw, N. Vinckenbosch, P. Liu, R. Yasmin, B. Desvergne, W. Wahli, and N. Noy Selective Cooperation between Fatty Acid Binding Proteins and Peroxisome Proliferator-Activated Receptors in Regulating Transcription Mol. Cell. Biol., July 15, 2002; 22(14): 5114 - 5127. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. S. Budhu and N. Noy Direct Channeling of Retinoic Acid between Cellular Retinoic Acid-Binding Protein II and Retinoic Acid Receptor Sensitizes Mammary Carcinoma Cells to Retinoic Acid-Induced Growth Arrest Mol. Cell. Biol., April 15, 2002; 22(8): 2632 - 2641. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Ruhl, C. Plum, M. M. A. Elmazar, and H. Nau Embryonic Subcellular Distribution of 13-cis- and All-trans-Retinoic Acid Indicates Differential Cytosolic/Nuclear Localization Toxicol. Sci., September 1, 2001; 63(1): 82 - 89. [Abstract] [Full Text] [PDF] |
||||
![]() |
Y. Hippo, M. Yashiro, M. Ishii, H. Taniguchi, S. Tsutsumi, K. Hirakawa, T. Kodama, and H. Aburatani Differential Gene Expression Profiles of Scirrhous Gastric Cancer Cells with High Metastatic Potential to Peritoneum or Lymph Nodes Cancer Res., February 1, 2001; 61(3): 889 - 895. [Abstract] [Full Text] |
||||
![]() |
A. Radominska-Pandya, G. Chen, V. M. Samokyszyn, J. M. Little, W. E. Gall, G. Zawada, N. Terrier, J. Magdalou, and P. Czernik Application of photoaffinity labeling with [3H] all trans- and 9-cis-retinoic acids for characterization of cellular retinoic acid-binding proteins I and II Protein Sci., January 1, 2001; 10(1): 200 - 211. [Abstract] [Full Text] |
||||
![]() |
T. Helledie, M. Antonius, R. V. Sørensen, A. V. Hertzel, D. A. Bernlohr, S. Kølvraa, K. Kristiansen, and S. Mandrup Lipid-binding proteins modulate ligand-dependent trans-activation by peroxisome proliferator-activated receptors and localize to the nucleus as well as the cytoplasm J. Lipid Res., November 1, 2000; 41(11): 1740 - 1751. [Abstract] [Full Text] |
||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| All ASBMB Journals | Molecular and Cellular Proteomics |
| Journal of Lipid Research | ASBMB Today |